When Lauren Marchi entered college as a freshman at American University in Washington, DC, she was a classically trained pianist and ballerina. She had aspirations of pursuing degrees in piano performance and marketing while dancing on the side, but early in her senior year she was forced to question her well-laid plans.

On July 13th, the Global Healthy Living Foundation, working with the Coalition of State Rheumatology Organizations and the Arthritis Foundation, in cooperation with the Congressional Arthritis Caucus, co-hosted a congressional briefing on “Biosimilars for Arthritis Patients: Challenges and Opportunities.”

Dr. Neal Raisman, a GHLF advocate who lost his son Isaac to meningitis in 2005, provided testimony before the ACIP, urging the Committee to approve the meningitis B vaccine for routine clinical use.

Katherine “Kat” Macfarlane, JD, who has rheumatoid arthritis and inflammatory eye disease, spoke at a briefing held at the House of Representatives on Monday about regulation of biosimilars.

Patient Advocate Cindi Brannum played a key role in the passing of Texas House Bill 751, which was signed into law by Governor Abbott on June 19th!

Please join the Coalition of State Rheumatology Organizations, the American
Autoimmune Related Diseases Association, the Global Healthy Living Foundation,
and the Arthritis Foundation, in cooperation with the Congressional Arthritis
Caucus, for a briefing on implementation of the Biologics Price Competition and
Innovation Act.

  (Upper Nyack, NY) The Global Healthy Living Foundation, working with the Coalition of State Rheumatology Organizations (CRSO) and the Arthritis Foundation, in cooperation with the Congressional Arthritis Caucus, will co-host a congressional briefing to address the forthcoming availability of biosimilars in light of the U.S. Food and Drug Administration (FDA) not providing final guidance […]

Rheumatoid arthritis patient advocates for continued access to medication in North Dakota

The U.S. Food and Drug Administration is months away from approving the first biosimilar drugs, but a bill advanced by a legislative committee Monday would help Utah prepare for that day.

For patients who are uninsured or underinsured, new treatments on the cutting edge of medicine called biosimilars have the potential to expand access and save lives.